Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

Bristol Myers Squibb Co BMY and Exelixis Inc EXEL announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma.

  • The updated results will be featured at the American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium.
  • With a median follow-up of 32.9 months, Opdivo/Cabometyx combo continued to show meaningful improvements in median overall survival (37.7 months vs. 34.3 months). 
  • It demonstrated a 30% reduction in the risk of death compared to sunitinib.
  • Progression-free survival benefits were maintained, with the combination continuing to double median PFS vs. sunitinib (16.6 months vs. 8.3 months.
  • Objective response rates were sustained, with nearly twice as many patients responding to Opdivo/Cabometyx combo vs. sunitinib (55.7% vs. 28.4%). 
  • Responses were also more durable with the combination, with a median DoR of 23.1 months, compared to 15.1 months with sunitinib.
  • Additionally, higher percentage of patients experienced any tumor shrinkage benefits with Opdivo/Cabometyx combo vs. sunitinib across lung (90.5% vs. 76.0%), lymph node (88.4% vs. 72.6%), kidney (89.0% vs. 71.6%), liver (72.7% vs. 53.8%) and bone (85.2% vs. 65.0%) target lesions.
  • Price Action: EXEL shares closed at $18.59 on Monday. BMY shares are up 0.36% at $67.05 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 3 Trialrenal cell carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!